Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1G93A and NSG animal models.

Izrael M, Slutsky SG, Admoni T, Cohen L, Granit A, Hasson A, Itskovitz-Eldor J, Krush Paker L, Kuperstein G, Lavon N, Yehezkel Ionescu S, Solmesky LJ, Zaguri R, Zhuravlev A, Volman E, Chebath J, Revel M.

Stem Cell Res Ther. 2018 Jun 6;9(1):152. doi: 10.1186/s13287-018-0890-5.

2.

Suspension culture of undifferentiated human embryonic and induced pluripotent stem cells.

Amit M, Chebath J, Margulets V, Laevsky I, Miropolsky Y, Shariki K, Peri M, Blais I, Slutsky G, Revel M, Itskovitz-Eldor J.

Stem Cell Rev Rep. 2010 Jun;6(2):248-59. doi: 10.1007/s12015-010-9149-y.

PMID:
20431964
3.

Survival, differentiation, and reversal of heroin neurobehavioral teratogenicity in mice by transplanted neural stem cells derived from embryonic stem cells.

Kazma M, Izrael M, Revel M, Chebath J, Yanai J.

J Neurosci Res. 2010 Feb 1;88(2):315-23. doi: 10.1002/jnr.22193.

PMID:
19746435
4.

Induction of neuronal and myelin-related gene expression by IL-6-receptor/IL-6: a study on embryonic dorsal root ganglia cells and isolated Schwann cells.

Zhang PL, Levy AM, Ben-Simchon L, Haggiag S, Chebath J, Revel M.

Exp Neurol. 2007 Dec;208(2):285-96. Epub 2007 Sep 19.

PMID:
17963753
5.

Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo.

Izrael M, Zhang P, Kaufman R, Shinder V, Ella R, Amit M, Itskovitz-Eldor J, Chebath J, Revel M.

Mol Cell Neurosci. 2007 Mar;34(3):310-23. Epub 2006 Dec 28.

PMID:
17196394
6.

Increased myelinating capacity of embryonic stem cell derived oligodendrocyte precursors after treatment by interleukin-6/soluble interleukin-6 receptor fusion protein.

Zhang PL, Izrael M, Ainbinder E, Ben-Simchon L, Chebath J, Revel M.

Mol Cell Neurosci. 2006 Mar;31(3):387-98. Epub 2005 Dec 1.

PMID:
16325417
7.

Chimeric molecule IL-6/soluble IL-6 receptor is a potent mitogen for fetal hepatocytes.

Zvibel I, Brill S, Kariv R, Traister A, Golan T, Chebath J, Halpern Z, Revel M, Oren R.

J Cell Physiol. 2004 Aug;200(2):245-52.

PMID:
15174094
8.
9.

C/EBP-delta induction by gp130 signaling. Role in transition to myelin gene expressing phenotype in a melanoma cell line model.

Kamaraju AK, Adjalley S, Zhang P, Chebath J, Revel M.

J Biol Chem. 2004 Jan 30;279(5):3852-61. Epub 2003 Nov 3.

10.

Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype.

Slutsky SG, Kamaraju AK, Levy AM, Chebath J, Revel M.

J Biol Chem. 2003 Mar 14;278(11):8960-8.

11.

Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling.

Kamaraju AK, Bertolotto C, Chebath J, Revel M.

J Biol Chem. 2002 Apr 26;277(17):15132-41. Epub 2002 Feb 5.

12.

Stimulation of myelin gene expression in vitro and of sciatic nerve remyelination by interleukin-6 receptor-interleukin-6 chimera.

Haggiag S, Zhang PL, Slutzky G, Shinder V, Kumar A, Chebath J, Revel M.

J Neurosci Res. 2001 Jun 15;64(6):564-74.

PMID:
11398179
14.
16.

Involvement of receptor-bound protein methyltransferase PRMT1 in antiviral and antiproliferative effects of type I interferons.

Altschuler L, Wook JO, Gurari D, Chebath J, Revel M.

J Interferon Cytokine Res. 1999 Feb;19(2):189-95.

PMID:
10090404
17.

Increased sensitivity of IL-6-deficient mice to carbon tetrachloride hepatotoxicity and protection with an IL-6 receptor-IL-6 chimera.

Katz A, Chebath J, Friedman J, Revel M.

Cytokines Cell Mol Ther. 1998 Dec;4(4):221-7.

PMID:
10068056
18.

Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities.

Chebath J, Fischer D, Kumar A, Oh JW, Kolett O, Lapidot T, Fischer M, Rose-John S, Nagler A, Slavin S, Revel M.

Eur Cytokine Netw. 1997 Dec;8(4):359-65.

19.
20.
22.
23.

Interleukin-6: effects on tumor models in mice and on the cellular regulation of transcription factor IRF-1.

Revel M, Katz A, Eisenbach L, Feldman M, Haran-Ghera N, Harroch S, Chebath J.

Ann N Y Acad Sci. 1995 Jul 21;762:342-55; discussion 355-6. No abstract available.

PMID:
7545371
24.

Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.

Halimi H, Eisenstein M, Oh JW, Revel M, Chebath J.

Eur Cytokine Netw. 1995 May-Jun;6(3):135-43. Erratum in: Eur Cytokine Netw 1995 Jul-Dec;6(4):219.

PMID:
8589270
25.
26.
29.

Interleukin-6 activates and regulates transcription factors of the interferon regulatory factor family in M1 cells.

Harroch S, Gothelf Y, Watanabe N, Revel M, Chebath J.

J Biol Chem. 1993 Apr 25;268(12):9092-7.

30.

Possible involvement of (2'5')oligoadenylate synthetase activity in pre-mRNA splicing.

Sperling J, Chebath J, Arad-Dann H, Offen D, Spann P, Lehrer R, Goldblatt D, Jolles B, Sperling R.

Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10377-81.

31.

Terminal differentiation of myeloleukemic M1 cells induced by IL-6: role of endogenous interferon.

Gothelf Y, Raber J, Chen L, Schattner A, Chebath J, Revel M.

Lymphokine Cytokine Res. 1991 Oct;10(5):369-75.

PMID:
1768740
32.

Specific regulation of the 100 kDa 2-5 A synthetase by protein kinase C.

Raber J, Eldar H, Lehrer R, Chebath J, Livneh E.

Eur Cytokine Netw. 1991 Aug-Sep;2(4):281-90.

PMID:
1756233
33.

The murine 2-5A synthetase locus: three distinct transcripts from two linked genes.

Rutherford MN, Kumar A, Nissim A, Chebath J, Williams BR.

Nucleic Acids Res. 1991 Apr 25;19(8):1917-24.

34.

Interleukin-6 induces the (2'-5') oligoadenylate synthetase gene in M1 cells through an effect on the interferon-responsive enhancer.

Cohen B, Gothelf Y, Vaiman D, Chen L, Revel M, Chebath J.

Cytokine. 1991 Mar;3(2):83-91.

PMID:
1888886
35.
36.

Synergism of type I and type II interferons in stimulating the activity of the same DNA enhancer.

Vaiman D, Pietrokovsky S, Cohen B, Benech P, Chebath J.

FEBS Lett. 1990 Jun 4;265(1-2):12-6.

37.

Production of two human 2',5'-oligoadenylate synthetase enzymes in Escherichia coli.

Mory Y, Vaks B, Chebath J.

J Interferon Res. 1989 Jun;9(3):295-304.

PMID:
2664013
38.
39.
40.
41.

Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection.

Chebath J, Benech P, Revel M, Vigneron M.

Nature. 1987 Dec 10-16;330(6148):587-8.

PMID:
2825034
42.

Interferon-responsive regulatory elements in the promoter of the human 2',5'-oligo(A) synthetase gene.

Benech P, Vigneron M, Peretz D, Revel M, Chebath J.

Mol Cell Biol. 1987 Dec;7(12):4498-504.

43.

Identification of 69-kd and 100-kd forms of 2-5A synthetase in interferon-treated human cells by specific monoclonal antibodies.

Hovanessian AG, Laurent AG, Chebath J, Galabru J, Robert N, Svab J.

EMBO J. 1987 May;6(5):1273-80.

44.

Four different forms of interferon-induced 2',5'-oligo(A) synthetase identified by immunoblotting in human cells.

Chebath J, Benech P, Hovanessian A, Galabru J, Revel M.

J Biol Chem. 1987 Mar 15;262(8):3852-7.

46.

Different mechanisms for activation of gene transcription by interferons alpha and gamma.

Faltynek CR, McCandless S, Chebath J, Baglioni C.

Virology. 1985 Jul 15;144(1):173-80.

PMID:
3933177
47.
48.

The human (2'-5') oligo A synthetase gene, structure of its two enzyme products and quick cell blot for clinical monitoring of its activation by interferons.

Chebath J, Benech P, Mory Y, Federman P, Berissi H, Gesang C, Forman J, Danovitch S, Lehrer R, Aloni N, et al.

Prog Clin Biol Res. 1985;202:149-61. No abstract available.

PMID:
2421298
49.
50.

Supplemental Content

Loading ...
Support Center